Actively Recruiting
Evaluating Risankizumab for Safety, Pharmacokinetics, and Treatment in Children With Moderate to Severe Crohns Disease Using Intravenous and Subcutaneous Dosing
Led by AbbVie · Updated on 2026-10-20
110
Participants Needed
85
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying risankizumab, a drug approved for adults with certain conditions, to evaluate its effects in children aged 2 to under 18 years with moderately to severely active Crohns Disease who have not responded well or are intolerant to other treatments. This Phase 3 study includes three groups by age and involves multiple study parts to assess how the drug moves through the body, its safety, and its impact on disease activity. Participants will receive risankizumab through an intravenous infusion during a 12-week induction phase. Those who complete this phase may enter a 52-week maintenance period where they receive one of two doses of the drug by subcutaneous injection without knowing which dose they get. Afterward, participants can join a 208-week open-label extension phase with risankizumab dosing based on their previous response. During the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, and questionnaires will be used to monitor disease activity and check for side effects. Key measures include clinical remission and endoscopic response at 12 and 64 weeks. Follow-up continues for about 140 days after treatment periods, allowing researchers to understand the drugs effects and safety over time.
CONDITIONS
Brief Title
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here